[go: up one dir, main page]

NO994303D0 - Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre - Google Patents

Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre

Info

Publication number
NO994303D0
NO994303D0 NO994303A NO994303A NO994303D0 NO 994303 D0 NO994303 D0 NO 994303D0 NO 994303 A NO994303 A NO 994303A NO 994303 A NO994303 A NO 994303A NO 994303 D0 NO994303 D0 NO 994303D0
Authority
NO
Norway
Prior art keywords
ylidenomethyl
phenylpyrrolidin
indole
dichloro
oxo
Prior art date
Application number
NO994303A
Other languages
English (en)
Other versions
NO994303L (no
Inventor
Zadeo Cimarosti
Paolo Maragni
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of NO994303D0 publication Critical patent/NO994303D0/no
Publication of NO994303L publication Critical patent/NO994303L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
NO994303A 1997-03-05 1999-09-03 Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre NO994303L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9704498.6A GB9704498D0 (en) 1997-03-05 1997-03-05 Chemical compound
PCT/EP1998/001146 WO1998039327A1 (en) 1997-03-05 1998-03-03 Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid

Publications (2)

Publication Number Publication Date
NO994303D0 true NO994303D0 (no) 1999-09-03
NO994303L NO994303L (no) 1999-11-03

Family

ID=10808697

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994303A NO994303L (no) 1997-03-05 1999-09-03 Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre

Country Status (29)

Country Link
EP (1) EP0966463A1 (no)
JP (1) JP2001513796A (no)
KR (1) KR20000075907A (no)
CN (1) CN1249750A (no)
AP (1) AP9901637A0 (no)
AR (1) AR011178A1 (no)
AU (1) AU6825198A (no)
BG (1) BG103779A (no)
BR (1) BR9808305A (no)
CA (1) CA2282851A1 (no)
CO (1) CO4940415A1 (no)
EA (1) EA199900710A1 (no)
EE (1) EE9900387A (no)
GB (1) GB9704498D0 (no)
HR (1) HRP980114A2 (no)
HU (1) HUP0002109A2 (no)
ID (1) ID24207A (no)
IL (1) IL131489A0 (no)
IS (1) IS5166A (no)
NO (1) NO994303L (no)
NZ (1) NZ337315A (no)
OA (1) OA11154A (no)
PE (1) PE51399A1 (no)
PL (1) PL335652A1 (no)
SK (1) SK119699A3 (no)
TR (1) TR199902117T2 (no)
WO (1) WO1998039327A1 (no)
YU (1) YU43499A (no)
ZA (1) ZA981791B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704499D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Method of manufacture
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2018284335A1 (en) 2017-06-12 2020-01-30 Glytech Llc. Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
AU6825198A (en) 1998-09-22
ID24207A (id) 2000-07-13
BG103779A (en) 2000-06-30
AR011178A1 (es) 2000-08-02
SK119699A3 (en) 2000-05-16
TR199902117T2 (xx) 2000-03-21
KR20000075907A (ko) 2000-12-26
JP2001513796A (ja) 2001-09-04
PE51399A1 (es) 1999-06-07
IL131489A0 (en) 2001-01-28
CO4940415A1 (es) 2000-07-24
CA2282851A1 (en) 1998-09-11
AP9901637A0 (en) 1999-09-30
EA199900710A1 (ru) 2000-04-24
EE9900387A (et) 2000-04-17
CN1249750A (zh) 2000-04-05
NZ337315A (en) 2001-02-23
HUP0002109A2 (hu) 2001-04-28
BR9808305A (pt) 2000-05-16
GB9704498D0 (en) 1997-04-23
EP0966463A1 (en) 1999-12-29
HRP980114A2 (en) 1998-12-31
IS5166A (is) 1999-08-27
PL335652A1 (en) 2000-05-08
YU43499A (sh) 2000-12-28
OA11154A (en) 2003-04-16
WO1998039327A1 (en) 1998-09-11
NO994303L (no) 1999-11-03
ZA981791B (en) 1999-09-03

Similar Documents

Publication Publication Date Title
DE69811892D1 (de) Kristalline form von omeprazol-natriumsalz
DE59912742D1 (de) Substituierte pyrazolderivate
NO20013665L (no) Kaliumsalt av (S)-omeprazol
EE04772B1 (et) 3-arüül-2-hüdroksüpropaanhappe derivaat (I)
PT1077957E (pt) Derivados do acido oxi-iminoalcanoico
DK1001934T3 (da) Indolforbindelser som COX-2-inhibitorer
NO20011083L (no) Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
FI950568A7 (fi) 5-heteroaryyli-indolijohdannaiset
NO994303D0 (no) Krystallinsk hydrert natriumsalt av (E)-4,6-diklor-3-(2-okso-1-fenylpyrrolidin-3-ylidenmetyl)-1H-indol-2-karboksylsyre
NO996448D0 (no) System for intervensjon av undervannsbrønner
DE69824279D1 (de) Stabilisiertes Natriumcarbonat-Peroxyhydrat
FI970314L (fi) Stabiloitu natriumkarbonaattiperoksihydraatti
HK1022899A (en) Crystalline hydrated sodium salt of (e)-4, 6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid
FI960424A0 (fi) Substituoidut indolijohdannaiset
DK1068198T3 (da) 5-Heteroarylsubstituerede indoler
DE50004107D1 (de) Natriumvalproat-granulat mit verringerter hygroskopizität
DZ3463A1 (fr) Cristaux d'inhibiteurs de l'echangeur sodium-hydrogene de type 1
NO20010972L (no) System for overföring av datapakker
DE50013257D1 (de) Hochalkalisches kristallines Natriumsilikat
ATE414059T1 (de) Kristalline form des natriumsalzes von 5-chlor-2- methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid
SI0991641T1 (en) Crystalline form of omeprazole sodium salt
ID21508A (id) Proses untuk pembuatan senyawa-senyawa 1-(amino-alkil) indol.
NO961495D0 (no) System for produksjon av fiskeline

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application